Save for clinic
📖 Full analysis: Desktop version — complete efficacy tables, safety detail, subgroup data, and clinical implications
🎯 Clinical Bottom Line
In patients with clinically node-negative breast cancer and one or two sentinel-node macrometastases, omitting completion axillary dissection does not compromise recurrence-free survival — regardless of whether patients undergo breast-conserving surgery or mastectomy. When combined with modern systemic therapy and nodal radiation, sentinel-node biopsy alone provides equivalent disease control. This extends beyond prior ACOSOG Z0011 evidence by including mastectomy patients and mandating nodal radiation.
Key Result: 5-year recurrence-free survival (per-protocol) — 89.7% vs 88.7%, HR 0.89 (95% CI 0.66–1.19; P<0.001 for noninferiority)
Safety Signal: No traditional AE data reported (surgical trial). Lymphedema and QOL outcomes pending.
✅ Patient Eligibility
Must Have:
- Clinically node-negative (cN0) breast cancer
- Tumor stage T1, T2, or T3
- 1 or 2 sentinel-node macrometastases (>2 mm)
- Preoperative axillary ultrasonography
Cannot Have:
- Extraaxillary regional or distant metastases
- Prior invasive breast cancer
- Contraindications to radiation therapy or systemic treatment
💊 Treatment Overview
Experimental Arm: Sentinel-Node Biopsy Only
Sentinel-node biopsy without completion axillary dissection. Adjuvant systemic treatment and radiation per national guidelines.
Control Arm: Completion Axillary-Lymph-Node Dissection
Sentinel-node biopsy plus completion dissection. Same adjuvant systemic and radiation approach.
~89% of patients in both arms received nodal radiation therapy. ~65% received chemotherapy; ~93% endocrine therapy.
⚠️ Safety Snapshot
No pharmacological adverse event table — this is a surgical trial. Key surgical outcome data pending:
- Lymphedema rates: Not yet reported (3-year PRO data pending)
- Quality of life: Not yet reported
- Treatment-related deaths: Not reported in this publication
Deaths
| Biopsy Only | Dissection | |
|---|---|---|
| Total deaths | 62 | 69 |
| Breast cancer deaths | 24 | 31 |
| Other/unknown cause | 38 | 38 |
📊 Key Numbers
Median follow-up: 46.8 months
| Outcome | Biopsy Only (n=1,335) | Dissection (n=1,205) | HR (95% CI) | p-value |
|---|---|---|---|---|
| 5-yr RFS (secondary, formally tested) | 89.7% | 88.7% | 0.89 (0.66–1.19) | P<0.001 (noninf) |
| 5-yr OS (primary, not yet mature) | 92.9% | 92.0% | Not reported | Pending |
| 5-yr BCSS | 97.1% | 96.6% | Not reported | Not reported |
Regional recurrence: 0.4% vs 0.5%. Distant recurrence: 3.3% vs 4.4%.
Non-sentinel-node metastases found in 34.5% of patients who underwent dissection — residual disease effectively managed by systemic therapy and radiation in the biopsy-only arm.
🔬 Key Comparator Context
| Trial | Intervention | Population | Key Result | Ref |
|---|---|---|---|---|
| SENOMAC | SNB only vs ALND | cN0, T1–T3, 1–2 SN macro; BCS or mastectomy | 5-yr RFS: HR 0.89, noninferiority met | [1] |
| Z0011 | SNB only vs ALND | cN0, T1–T2, 1–2 pos SN; BCS only | 10-yr OS: 86.3% vs 83.6%, noninf | [4] |
| AMAROS | Axillary RT vs ALND | cN0, T1–T2, pos SN | 10-yr axillary recurrence <2% both arms | [5] |
Cross-trial comparisons are limited by differences in populations, designs, and endpoints.
🔍 Subgroups to Watch
Mastectomy patients: HR 0.79 (95% CI 0.52–1.21) — at least as favorable as BCS; critical since Z0011 excluded this group
T3 tumors: HR 0.47 (95% CI 0.16–1.39) — point estimate strongly favors biopsy only, but small numbers (n=147)
Extracapsular extension present: HR 0.94 (95% CI 0.58–1.54) — no detriment from omitting dissection even with ECE
ER+/HER2+ subgroup: HR 0.26 (95% CI 0.07–0.96) — striking signal but very few events (3 vs 10); hypothesis-generating
Subgroup analyses were not powered for formal comparisons. Results are hypothesis-generating.
📋 Regulatory Status
| Region | Status |
|---|---|
| FDA | Not applicable — surgical strategy, not pharmaceutical |
| Guidelines | NCCN and European guidelines trending toward de-escalation of axillary surgery in this population [3] |
⚠️ Verify current guideline recommendations before clinical application.
⚡ Grey Zones
- Overall survival noninferiority not yet formally demonstrated — current result is on secondary endpoint only
- Patients with ≥3 sentinel-node macrometastases were excluded — safety of omitting dissection unknown in heavier nodal burden
- ~89% received nodal radiation; results may not apply to patients who do not receive nodal RT
- Lymphedema and quality-of-life data still pending — the primary argument for de-escalation lacks quantitative within-trial support
- Large consent withdrawal asymmetry (131 vs 11) suggests per-protocol dissection group may be a selected population
📖 Full Analysis
Read the complete desktop article with full efficacy tables, event breakdown, all subgroup data, comparator trial context, and clinical implications at kill-cancer.com
About the Author
Andrew Stevenson is the founder and systems architect of kill-cancer.com. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces to its source publication. Zero calculation. Zero editorializing. Zero hallucination. Five siblings lost to cancer built the urgency. The engineering builds the trust.
📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum
For healthcare professionals only. Not medical advice. Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability. Consult NCCN guidelines and institutional protocols.
References
- de Boniface J, Filtenborg Tvedskov T, Engberg Damsgaard T, et al. Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases. N Engl J Med. 2024. doi:10.1056/NEJMoa2313487
- Not applicable — surgical strategy trial.
- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. National Comprehensive Cancer Network. Accessed March 2026.
- Giuliano AE, Ballman KV, McCall L, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017;318(10):918-926.
- Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS). Lancet Oncol. 2014;15(12):1303-1310.
- Goyal A, Dodwell D, Reed MW, Coleman RE. Axillary treatment for patients with early breast cancer and one or two positive sentinel nodes (POSNOC). Lancet. 2023;402(10400):546-554.